Mobile World Congress 2015 Health & Wellness Track #MWC15

1. CCHA: China Connected Health Alliance

2. China: Challenges
Connected health faces key challenges with current attempts to
penetrate China’s nearly $70 Billion USD medical industry. The
various obstacles include:
• highly fragmented and inefficient domestic pharmaceutical markets
• absence of protection and enforcement on intellectual property rights
• lack of visibility for drug approval procedures
• poor corporate support and communication for drug research
• government bias against foreign corporations

3. China: Markets
• Almost 10% of China’s population is +65 in age (100 million people)
• Standards of living in China grow by 10% each year
• By 2030, 65% of China will be urbanized (according to the Chinese Census)
With these figures in mind, the growing urbanization of China increases demand for
greater medical attention and expertise
These provide HUGE opportunities for all health care providers
• Obesity, diabetes and lung cancer are amongst an all time high in younger populations
• Existing figures show from the last 10 years, China has spent nearly $500 Billion USD to
treat provide cumulative care: a faster mobile solution and more economic solution is
needed

4. China: Risks and Existing Case Studies
With the demand for adequate domestic suppliers, existng foreign corporatons have not been able to gain a majority foothold in
China.
Since the 2013 bribery scandal, at least 7 Big Pharmaceutcal corporatons have been accused with allegatons and penaltes related to
bribery of government officials, notwithstanding the current prevailing obstacles including:
• GlaxoSmithKline
• Merck
• Eli Lilly
• Roche
• Sanofi
• AstraZeneca
• Novarts
For example with out the full understanding of the Chinese market, a superimposed Westernized approach will only result in
superfcial market shares
(AstraZeneca at the moment of scandal had the most exposure; China only accounted for 6.9% of its total sales - Q2, 2013)

5. CCHA – The Alternative and Ecosystems
CCHA offers an integrated solution by applying the existing ECHA module to a
Chinese audience. This unifying approach takes the best qualities of the ECHA
with a Chinese focus. China's health industry can be divided into 5 basic
industrial groups:
• Health care institutions as the main health care industry
• Pharmaceuticals and medical equipment as the main pharmaceutical industry
• Traditional Chinese health care with food and product sales
• Service Industries with healthcare professionals, technology, managements
and patients
• A utilization and consolidation of the nations network and connectivity via an
eHealth digital platform

6. CCHA: Mission
As the China branch of ECHA, CCHA will focus on all health sectors in China. CCHA aims
toward transforming China’s healthcare to deliver economic benefits, as well as positive
progression for the global health industry.
This exclusive partnership of ECHA, CCHA and the China government with aid in bringing
together healthcare organizations, companies, and local government branches.
China’s health industry reaches nearly $70 Billion USD annually, and has a market size of
up to 1.4 billion people - making it one of the largest potential markets in the world.
Paired with the highest number of internet/mobile users in the world, CCHA aims to
communicate and address all the problems arisen from the inadequate systems,
equipment, facilities and even educational institutions.

7. CCHA: China Connected Health Alliance
www.cchalliance.cn